AC Immune
ACIU
AC Immune (ACIU) earnings history
Most recent quarter
- Fiscal period
- Q4 2025
- Period end
- Dec 31, 2025
- EPS actual
- −$0.18
- EPS estimate
- −$0.21
- EPS surprise
- +16.22%
- Revenue surprise
- −70.32%
- Revenue
- $428,876.00
- Revenue estimate
- $1.4M
- Reported
- Mar 13, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q4 2025 | Mar 13, 2026 | −$0.21 | −$0.18 | +16.22% | $428,876.00 | SEC |
| Q3 2025 | Nov 4, 2025 | −$0.23 | −$0.16 | +28.96% | $954,036.87 | SEC |
| Q2 2025 | Aug 5, 2025 | −$0.26 | −$0.26 | +0.00% | $1.6M | SEC |
| Q1 2025 | Apr 30, 2025 | −$0.23 | −$0.21 | +7.18% | $1.1M | SEC |
| Q4 2024 | Mar 13, 2025 | −$0.20 | −$0.18 | +14.55% | $1.3M | SEC |
| Q3 2024 | Nov 5, 2024 | −$0.16 | $0.06 | +136.62% | $30.1M | SEC |
| Q2 2024 | Aug 6, 2024 | $0.53 | −$0.26 | −148.37% | $764,150.10 | SEC |
| Q1 2024 | May 13, 2024 | −$0.15 | −$0.20 | −33.18% | $0.00 | SEC |
| Q4 2023 | Mar 14, 2024 | −$0.11 | −$0.06 | +47.53% | $17.6M | SEC |
| Q3 2023 | Nov 3, 2023 | $0.03 | −$0.20 | −695.76% | $0.00 | SEC |
| Q2 2023 | Aug 4, 2023 | −$0.22 | −$0.22 | −2.81% | $0.00 | SEC |
| Q1 2023 | Apr 28, 2023 | −$0.25 | −$0.23 | +9.33% | $0.00 | SEC |
| Q4 2022 | Mar 16, 2023 | −$0.27 | −$0.24 | +11.79% | $0.00 | SEC |
| Q3 2022 | Oct 28, 2022 | −$0.23 | −$0.16 | +32.63% | $4.0M | — |
| Q2 2022 | Jul 28, 2022 | −$0.25 | −$0.23 | +5.21% | $0.00 | — |
| Q1 2022 | Apr 28, 2022 | −$0.24 | −$0.24 | +0.33% | $0.00 | — |
| Q4 2021 | Mar 22, 2022 | $0.11 | −$0.27 | −346.62% | $0.00 | — |
| Q3 2021 | Nov 8, 2021 | −$0.29 | −$0.22 | +25.23% | $0.00 | — |
| Q2 2021 | Aug 4, 2021 | −$0.23 | −$0.28 | −24.03% | $162,276.19 | — |
| Q1 2021 | Apr 28, 2021 | −$0.24 | −$0.24 | +0.20% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did AC Immune (ACIU) last report earnings?
AC Immune last reported on Mar 13, 2026, covering fiscal Q4 2025.
Did ACIU beat earnings estimates?
Yes. AC Immune reported EPS of −$0.18 for Q4 2025 against a −$0.21 estimate — a 16.22% beat.
How much revenue did ACIU report last quarter?
AC Immune reported $428,876.00 in revenue for Q4 2025, against a consensus estimate of $1.4M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.